Literature DB >> 1334415

Do we know the site of action of cyclosporin?

B F Erlanger1.   

Abstract

The site and mode of action of cyclosporin A (CsA) have been subjects of study ever since CsA was discovered and demonstrated to be a selective suppressor of allograft rejection. In this article, Bernard Erlanger traces progress to date and presents evidence that the site of action is not cytoplasmic cyclophilin but a lymphocyte cell-surface receptor that might be related in structure to cyclophilin.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1334415     DOI： 10.1016/0167-5699(92)90023-Z

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  10 in total

1.  Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location.

Authors:  R J Bram; D T Hung; P K Martin; S L Schreiber; G R Crabtree
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

2.  Inhibition of T cell cAMP formation by cyclosporin A and FK506.

Authors:  H M Ockenfels; S N Wagner; P Oeljeklaus; B Schneck; G Nussbaum; K H Jakobs; M Goos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

Review 3.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

4.  Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669.

Authors:  Y Prinsloo; C E van Rensburg; R van der Walt; R Anderson
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

5.  Effects of dexamethasone and cyclosporin A on the accumulation of eosinophils in acute cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 6.  Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation.

Authors:  Ravi Starzl; Gerald Brandacher; W P Andrew Lee; Jaime Carbonell; Wensheng Zhang; Jonas Schnider; Vijay Gorantla; Stefan Schneeberger; Xin Xiao Zheng
Journal:  Clin Dev Immunol       Date:  2013-02-13

Review 7.  Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients.

Authors:  Eric Thervet; Frank Martinez; Christophe Legendre
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

Review 8.  Established and newly proposed mechanisms of chronic cyclosporine nephropathy.

Authors:  Hye Eun Yoon; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 2.884

Review 9.  Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.

Authors:  Eric Thervet
Journal:  Int J Nanomedicine       Date:  2006

Review 10.  Use of antioxidants to prevent cyclosporine a toxicity.

Authors:  Jinhwa Lee
Journal:  Toxicol Res       Date:  2010-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.